5-Amino-1MQ Human Trials: What Actually Exists

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

People search for 5-Amino-1MQ human trials. The honest answer is that there are none in the indexed literature, and the second honest answer is that there is no published pharmacokinetic study either. Writing that plainly is more useful than assembling preclinical results into something that reads like clinical evidence.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

What the evidence base actually contains

Evidence type	Status
Human clinical trials	None found
Published pharmacokinetics or half-life	None found
Mouse model work on NNMT inhibitors	Yes — 2018, Biochem Pharmacol
Target-level work on NNMT	Yes — 2025, Nature, in a different context
Cell-level enzyme inhibition	Yes, within the NNMT inhibitor literature
Independent replication of the mouse findings	Limited

Two rows deserve emphasis because they are what the searches are really asking about, and both are negative. We state them as “none found” rather than “none exist”: an unindexed or very recent study could exist. But a compound with clinical work behind it is normally easy to find, and this one is not.

The 2018 mouse study, read carefully

The study by Neelakantan and colleagues in Biochemical Pharmacology is the foundation of this compound’s reputation. It describes selective, membrane-permeable small-molecule inhibitors of nicotinamide N-methyltransferase in a mouse model.

Three features of it are worth separating:

Selectivity and membrane permeability are chemistry claims, tested in vitro, and they are the paper’s most transferable contribution. An inhibitor that cannot cross a membrane cannot reach a cytosolic enzyme.
The animal work is a mouse model with a specific induced condition. It supports the proposition that inhibiting this enzyme changes metabolism in that model.
The paper is about a class as much as about one molecule, which is why reading it as a study of one catalogue compound overstates it.

The 2025 Nature paper is about the target, not this compound

The study by Heide and colleagues reports that NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. It is strong work in a major journal, and it is frequently cited around this compound in a way that blurs an important distinction.

It is evidence that the target matters. It is not evidence about 5-Amino-1MQ specifically, nor about metabolic research applications. Target validation and compound validation are separate claims, and a reader evaluating a purchase is usually asking about the second.

The useful way to hold both: NNMT is a real enzyme with a growing literature establishing it as a meaningful target, and 5-Amino-1MQ is one tool compound used to probe it, whose own characterisation is thinner than the target’s.

The missing pharmacokinetics, and why it limits design

Without published disposition data, three things cannot be planned from the literature:

Exposure duration. A readout timed against an assumed half-life is timed against an assumption.
Comparisons with other compounds. Contrasting this inhibitor with an agent whose pharmacokinetics are published conflates potency and duration.
Translation between systems. Cell culture exposure and whole-animal exposure are different problems, and nothing in the literature bridges them for this molecule.

The practical substitute is to measure target engagement rather than infer it — substrate and product levels of the enzyme reaction, in the system being used. For an inhibitor this is the proximal readout, and it is available to any laboratory that can run the assay.

NNMT consumes a methyl donor and acts on nicotinamide, which places this compound adjacent to the NAD literature without being part of it. The 2021 review by Palmer and colleagues surveys NAD precursor approaches, and the distinction is worth keeping clear: a precursor adds substrate to a pathway; an enzyme inhibitor removes a route out of it. These are different interventions with different controls, as set out in NAD+ compared with nicotinamide riboside.

What to check about the material itself

Given the thin compound-level literature, material identity carries more weight than usual. The 2024 review by Kuril and colleagues sets out what full characterisation involves, and the principle transfers from peptides to small molecules: a single purity figure is not characterisation.

Purity with the method stated, and the salt form named — this compound is a permanently charged cation supplied as a salt.
Observed mass matching the cation, and residual solvent reported.
Appearance described, since discolouration is meaningful for an iodide salt.
Where possible, an activity measurement against the target enzyme, which is more informative than any chromatographic percentage.

The handling detail is in the 5-Amino-1MQ handling guide, and the compound background in what 5-Amino-1MQ is. Our 5-Amino-1MQ research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Scope note

This material is supplied for laboratory research use only. It is not a medicine, not a supplement, and not for human or veterinary use. Nothing above describes administration to any organism.

Open questions

Has any pharmacokinetic study of this compound been published anywhere indexed?
Have the 2018 mouse findings been reproduced by an independent group?
How selective is the compound against related methyltransferases that share cofactor chemistry?

Frequently asked questions

Are there published human trials of 5-Amino-1MQ?

No. A PubMed search for clinical work on nicotinamide N-methyltransferase inhibitors in humans returns nothing for this compound. The published evidence is preclinical: cell work and mouse models.

Is there a published half-life for it?

Not one we can find in the indexed literature. Searches that would surface a pharmacokinetic study for this compound return no disposition data, so any half-life figure circulating online does not have a published source behind it that we can verify.

What is the strongest published evidence?

A 2018 study in Biochemical Pharmacology describing selective, membrane-permeable small-molecule NNMT inhibitors in a mouse model, and a 2025 Nature paper reporting that NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. The second is about the target rather than this specific compound.

Does the absence of trials mean the compound does not work?

No. It means the question has not been answered in humans. Those are different statements, and conflating them in either direction is the most common error in reading this literature.

What should an experiment confirm first?

That the target enzyme is expressed in the system. An inhibitor produces nothing where there is nothing to inhibit, and a null result in a low-NNMT system carries no information about the compound.

References

Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PMID: 29155147 https://pubmed.ncbi.nlm.nih.gov/29155147/
Heide J, et al. NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025. PMID: 40702186 https://pubmed.ncbi.nlm.nih.gov/40702186/
Palmer RD, et al. Precursor comparisons for the upregulation of nicotinamide adenine dinucleotide. Novel approaches for better aging. Aging Med (Milton). 2021. PMID: 34553119 https://pubmed.ncbi.nlm.nih.gov/34553119/
Kuril AK, et al. Analytical considerations for characterization of generic peptide product: A regulatory insight. Anal Biochem. 2024. PMID: 39089363 https://pubmed.ncbi.nlm.nih.gov/39089363/